Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

Davis-based biological controls company Invasive Species Corp., founded by biologics pioneer Pam Marrone, has taken office ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...